



News Release

Cellzome Announces Extension of Molecular Pathway Collaboration

Boston, 10th July 2006 - Cellzome Inc. announced today that its research collaboration with Novartis has been extended for a further year until 30 June 2007.

During the initial phase of the collaboration Cellzome has been applying its proprietary technology both to the mapping of several different signaling pathways implicated in various diseases, and the detailed characterisation of several Novartis compounds. Novel drug discovery projects have resulted from this work.

Tim Edwards, Cellzome's CEO, said: "This collaboration continues to make progress and create novel intellectual property. Our two teams have been working very well together, as Cellzome continues to improve its technology and techniques. I look forward to another year of continued progress."

For further information please contact:

Cellzome AG

Tim Edwards
Chief Executive Officer
Tel: +49 (0) 6221-137 57-100
press@cellzome.com

Media Contact

Hogarth Partnership
John Olsen/Melanie Toyne-Sewell
Tel: +44 (0) 207 357 9477
mtoyne-sewell@hogarthpr.co.uk

About the Collaboration

In September 2004, Cellzome and Novartis entered into this collaboration that combines Cellzome's experience in chemical proteomics and pathway mapping with Novartis' insights into particular disease pathways and its expertise in sensitized cellular screens. The companies are charting the physical and functional protein maps of key cellular pathways of a variety of diseases, with the potential to select the best protein targets within these pathways for the development of new drug candidates. Cellzome's chemical proteomics expertise is also helping identify the role of active Novartis compounds in disease and their potential side effects. The work is being conducted between Cellzome's Heidelberg operations and Novartis' Developmental and Molecular Pathways group based in Cambridge MA. Novartis has made an equity investment in Cellzome Inc. and contributes research funding. There are also lead compound development options for both companies in exchange for licenses, milestone payments and royalties.